On Nov. 7, dental laser maker Biolase (NASDAQ:BLTI) released fiscal third-quarter earnings for the period ending Sept. 30.

  • Net revenues rose 46% to $17.1 million as international sales rose 84% to $5.9 million.
  • Biolase added medical-device distributor Henry Schein (NASDAQ:HSIC) as its exclusive North American marketer, a move that helped mark strong organic growth -- particularly the 20% increase in its flagship Waterlase MD system.
  • Gross profits rose 500 basis points to 50.5%, up from 45.5% of net revenues recorded last year.

(Figures in thousands, except per-share data)

Income Statement Highlights

Avg. Est.

Q3 2006

Q3 2005

Change

Sales

$14,900

$17,066

$11,655

46.4%

Net Profit

--

($1,007)

($5,231)

N/A

EPS

$0.08

($0.04)

($0.23)

N/A

Diluted Shares

23,580

23,150

1.9%

Get back to basics with a look at the income statement.

Margin Checkup

Q3 2006

Q3 2005

Change*

Gross Margin

50.48%

45.51%

4.97

Operating Margin

(6.64%)

(44.50%)

37.86

Net Margin

(5.90%)

(44.88%)

38.98

*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q3 2006

Q3 2005

Change

Cash + ST Invest.

$15,695

$7,880

99.2%

Accounts Rec.

$10,149

$6,280

61.6%

Inventory

$6,067

$10,530

(42.4%)

Liabilities

Q3 2006

Q3 2005

Change

Accounts Payable

$6,291

$6,900

(8.8%)

Long-Term Debt

$0

$0

N/A



Learn the ways of the balance sheet.

Cash Flow Highlights
This information was not available in the press release.

Find out why Fools always follow the money.

Related Companies:

  • BriteSmile (NASDAQ:BSML)
  • Palomar Medical Technologies (NASDAQ:PMTI)
  • Candela (NASDAQ:CLZR)

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so checkFool.com for more of our in-depth discussion of what the numbers mean.

Among the investors in Motley Fool CAPS, 60% think BioLase will outperform the market. Join today and add your voice to the new investor intelligence community.

At the time of publication, Fool contributor Rich Duprey owned shares of Candela. Fool rules are here.